^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Natrunix (vilamakitug)

    i
    Other names: XB2001
    Associations

    News

    Trials
    Company:
    XBiotech
    Drug class:
    IL-1α inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    Natrunix in Combination with Methotrexate for Rheumatoid Arthritis Treatment (clinicaltrials.gov)
    P2, N=108, Not yet recruiting, XBiotech, Inc.
    New P2 trial • Combination therapy
    |
    Natrunix (vilamakitug)
    4ms
    Natrunix in HLA-B27 Positive Subjects With Axial Spondyloarthritis (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, XBiotech, Inc.
    New P2 trial • Combination therapy
    |
    Natrunix (vilamakitug)
    4ms
    1-BETTER: XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=76, Completed, XBiotech, Inc. | Active, not recruiting --> Completed | Trial primary completion date: Feb 2024 --> Oct 2023
    Trial completion • Trial primary completion date • Combination therapy • Metastases
    |
    5-fluorouracil • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • Natrunix (vilamakitug)
    9ms
    TASKIN: Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine (clinicaltrials.gov)
    P1/2, N=160, Recruiting, Centre Georges Francois Leclerc | Not yet recruiting --> Recruiting | Trial completion date: Mar 2026 --> Oct 2026 | Trial primary completion date: Mar 2024 --> Oct 2026
    Enrollment open • Trial completion date • Trial primary completion date • Metastases
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    oxaliplatin • irinotecan • Lonsurf (trifluridine/tipiracil) • Natrunix (vilamakitug)
    11ms
    Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis (clinicaltrials.gov)
    P2, N=210, Recruiting, XBiotech, Inc. | Not yet recruiting --> Recruiting | N=150 --> 210 | Trial completion date: Feb 2023 --> Aug 2024 | Trial primary completion date: Dec 2022 --> Jun 2024
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    Natrunix (vilamakitug)
    1year
    1-BETTER: XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=69, Active, not recruiting, XBiotech, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Aug 2023 --> May 2024 | Trial primary completion date: Jul 2023 --> Feb 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    5-fluorouracil • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • Natrunix (vilamakitug)
    over2years
    1-BETTER: XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=69, Recruiting, XBiotech, Inc. | Trial completion date: Oct 2022 --> Aug 2023 | Trial primary completion date: Apr 2022 --> Jul 2023
    Trial completion date • Trial primary completion date • Combination therapy
    |
    CD14 (CD14 Molecule)
    |
    5-fluorouracil • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • Natrunix (vilamakitug)
    almost3years
    TASKIN: Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine (clinicaltrials.gov)
    P1/2, N=160, Not yet recruiting, Centre Georges Francois Leclerc
    Clinical • New P1/2 trial
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    oxaliplatin • irinotecan • Lonsurf (trifluridine/tipiracil) • Natrunix (vilamakitug)
    over3years
    1-BETTER: XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=69, Recruiting, XBiotech, Inc. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    CD14 (CD14 Molecule)
    |
    5-fluorouracil • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • Natrunix (vilamakitug)
    over3years
    1-BETTER: XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=69, Not yet recruiting, XBiotech, Inc.
    Clinical • New P1/2 trial • Combination therapy
    |
    CD14 (CD14 Molecule)
    |
    5-fluorouracil • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • Natrunix (vilamakitug)